NervGen Pharma Corp.

NervGen Pharma today announced that the Company has elected to voluntarily delist its common shares from the TSX Venture Exchange, effective March 16, 2026. The Company’s common shares will continue to trade on Nasdaq under the symbol “NGEN,” and no action is required by shareholders. All shareholders, including Canadian shareholders, will continue to maintain full trading access on Nasdaq. Read the full news release: nervgen.com/nervgen-pharma… #SCI #SpinalCordInjury

NervGen today appointed Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as Senior Vice President (SVP), Patient Advocacy and Clinical Affairs. nervgen.com/nervgen-pharma… #SCI

NervGen today announced that Adam Rogers, MD, President and Chief Executive Officer, and other members of the Company’s executive leadership team, are scheduled to participate in multiple upcoming investor conferences. nervgen.com/nervgen-pharma… #SCI

NervGen today announced it will present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium, which is being held February 15-17, 2026, in Washington, DC. nervgen.com/nervgen-pharma… #SCI #SpinalCordInjury #CNS #NeuroRepair #Biotech

NervGen today announced it has appointed Adam Rogers, MD, as President and CEO. Dr. Rogers will continue leading the Company’s growth and execution of its mission to transform the lives of individuals living with spinal cord injury. nervgen.com/nervgen-pharma… #SCI

🎉A proud moment for our team! NervGen celebrated its @Nasdaq listing by ringing the closing bell yesterday in Times Square. A significant milestone and the beginning of an exciting year ahead. View the full ceremony: nasdaq.com/events/nervgen… #SCI #SpinalCordInjury

NervGen Pharma today announced that it will ring the closing bell at the Nasdaq Stock Market on Thursday, January 22, 2026, in New York City. nervgen.com/nervgen-pharma… #SCI #SpinalCordInjury

NervGen will be on the ground next week at #JPM2026 Jan 12-15 in San Francisco. We look forward to connecting with global industry leaders as we continue advancing NVG-291 to transform the lives of individuals living with spinal cord injury. #JPM26 #SCI

NervGen Pharma today announced that the company's common shares have been approved for listing on Nasdaq and will begin trading today under the symbol “NGEN.” nervgen.com/nervgen-pharma… #SCI #SpinalCordInjury

Thank you, @Forbes and @TheAlexKnapp, for featuring NVG-291 in this week’s edition of The Prototype!

NervGen CEO Adam Rogers spoke with @BioSpace about the unprecedented CONNECT SCI data showing NVG-291 improved function, independence & quality of life in chronic #SCI with reported durability up to 1 year after the 16-week study period. biospace.com/drug-developme… #SpinalCordInjury

NervGen reports its third quarter 2025 financial results and provides business updates. Read the full release here: nervgen.com/nervgen-pharma… #SCI #SpinalCordInjury #News

NervGen today announced expanded CONNECT SCI Study data demonstrating unprecedented durable improvement in function, independence, and quality of life in individuals living with chronic SCI. nervgen.com/nervgen-pharma… #SCI #SpinalCordInjury #News

NervGen today announced it is conducting a non-brokered private placement. The financing will include participation from new and existing investors, including SCI Ventures and the Paul and Phyllis Fireman Charitable Foundation. nervgen.com/nervgen-pharma… #SCI #SpinalCordInjury

Our CEO Adam Rogers, MD, will join the #BioFuture2025 panel, “Rewiring Minds: Breakthroughs in Brain & CNS Health,” exploring how advances in neuroscience are transforming healthcare. 🗓️ Oct 13 | 🕙 11 AM |📍 NYC biofuture.com #SCI #SpinalCordInjury #CNS #Biotech

It's #SpinalCordInjuryAwarenessMonth! Catch up with our CEO, Adam Rogers, MD, on the @ProgressPotent1 podcast with @irat1onal where he highlights NVG-291, the urgent need in SCI, and our mission to transform the lives of people living with #SCI. youtube.com/watch?v=9tG1_l…

📊 The "NVG-291 in Spinal Cord Injury Subjects" trial at Shirley Ryan AbilityLab is currently the most inquired trial on SCITrialsFinder.NET with almost 1500 inquiries via our website as of Q2 2025. 💡 NervGen also just published further updates: nervgen.com/nervgen-pharma…

Today is #WorldSpinalCordInjuryDay. We’re developing NVG-291, a first-in-class therapy, and the first pharmacologic candidate designed to enable nervous system repair—because recovery is possible for those living with spinal cord injury. nervgen.com #WorldSCIDay

NervGen today announced its second quarter 2025 financial results, including a letter to shareholders from Adam Rogers, MD, the Company’s Chairman and Interim CEO, providing a detailed business update. nervgen.com/nervgen-pharma… #SCI #News

NervGen today announced positive preclinical results of two @DeptofDefense sponsored studies in models of blast-induced sensorineural hearing loss and peripheral nerve injury, reinforcing the broad therapeutic application of NVG-291. nervgen.com/nervgen-pharma… #SCI #News